The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
The double dealing of cyclin D1
Open accessAbstract
The cell cycle is tightly regulated by cyclins and their catalytic moieties, the cyclin-dependent kinases (CDKs). Cyclin D1, in association with CDK4/6, acts as a mitogenic sensor and integrates extracellular mitogenic signals and cell cycle progression. When deregulated (overexpressed, accumulated, inappropriately located), cyclin D1 becomes an oncogene and is recognized as a driver of solid tumors and hemopathies. Recent studies on the oncogenic roles of cyclin D1 reported non-canonical functions dependent on the partners of cyclin D1 and its location within tumor cells or tissues. Support for these new functions was provided by various mouse models of oncogenesis. Finally, proteomic and transcriptomic data identified complex cyclin D1 networks. This review focuses on these aspects of cyclin D1 pathophysiology, which may be crucial for targeted therapy.Abbreviations: aa, amino acid; AR, androgen receptor; ATM, ataxia telangectasia mutant; ATR, ATM and Rad3-related; CDK, cyclin-dependent kinase; ChREBP, carbohydrate response element binding protein; CIP, CDK-interacting protein; CHK1/2, checkpoint kinase 1/2; CKI, CDK inhibitor; DDR, DNA damage response; DMP1, cyclin D-binding myb-like protein; DSB, double-strand DNA break; DNA-PK, DNA-dependent protein kinase; ER, estrogen receptor; FASN, fatty acid synthase; GSK3β, glycogen synthase-3β; HAT, histone acetyltransferase; HDAC, histone deacetylase; HK2, hexokinase 2; HNF4α, and hepatocyte nuclear factor 4α; HR, homologous recombination; IR, ionizing radiation; KIP, kinase inhibitory protein; MCL, mantle cell lymphoma; NHEJ, non-homologous end-joining; PCAF, p300/CREB binding-associated protein; PGC1α, PPARγ co-activator 1α; PEST, proline-glutamic acid-serine-threonine, PK, pyruvate kinase; PPAR, peroxisome proliferator-activated receptor; RB1, retinoblastoma protein; ROS, reactive oxygen species; SRC, steroid receptor coactivator; STAT, signal transducer and activator of transcription; TGFβ, transforming growth factor β; UPS, ubiquitin-proteasome system; USP22, ubiquitin-specific peptidase 22; XPO1 (or CRM1) exportin 1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Cyclin D1 is a major driver of multiple cancers (44) including MM (45), through overexpression in either the cytoplasm or nucleus where it promotes tumor invasion/metastasis or deregulation of cell cycle control/enhanced proliferation, respectively.”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Cell migration and invasion are hallmarks of cancer, leading to tumor cell expansion and dissemination through metastasis [95].”
BackgroundEnrichr: a comprehensive gene set enrichment analysis web server 2016 update
Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw377 · Cited by 10,799 · cited 2×
“The 153 proteins identified as cyclin D1 interactors in at least one of the five cancer cell line tested by Sicinski’s group (mantle cell lymphoma, breast cancers, pharyngeal cancer, colon cancer [8],) were analyzed with the Enrichr tool [124] for enriched WikiPathways [125] The top 20 enriched pathways are indicated.”
BackgroundMethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · cited 2×
“Indeed, the CCND1 gene encoding cyclin D1 is the second most frequently amplified locus in solid cancers [4].”
BackgroundCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“Diverse heterodimeric complexes form, with D-type cyclins (D1, D2 and D3) associating with CDK4 or CDK6 (CDK4/6, two serine/threonine kinases functionally redundant in most tissues [1]), to control the progression through the G1 phase, the G1-to-S phase transition, thereby initiating DNA replication [2].”
BackgroundComprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340 · cited 1×
“Cyclin D1 is overexpressed in many human solid cancers, including breast cancers, particularly those with the estrogen receptor (ER)-positive subtype [37], head and neck squamous cell carcinoma [38], pancreatic cancer [39], melanoma [40], endometrial cancer [41], colorectal carcinoma [42], and non-small cell lung carc…”
BackgroundGlycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Cell adhesion: integrating cytoskeletal dynamics and cellular tension
Parsons, J. T., Horwitz, A. R., & Schwartz, M. A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2957 · Cited by 1,988 · cited 2×
“[96] Parsons JT, Horwitz AR, Schwartz MA.”
BackgroundATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,961 · cited 1×
“Upon DNA damage, DNA-PK (DNA-dependent protein kinase), ATM (ataxia telangiectasia mutant) and ATR (ATM and Rad3-related) apical kinases and their downstream effectors, including the checkpoint kinases (CHK1/ 2), activate the DDR (DNA damage response) pathway [83].”
BackgroundCell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858 · cited 2×
“Hepatocarcinomas, colon carcinomas and skin papillomas have been shown to result from the overexpression of cyclin D1, in the appropriate transgenic mouse models [27].”
BackgroundCDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · cited 2×
“[22] Goel S, DeCristo MJ, Watt AC, et al.”
Background
Research works printed but not linked: 4
- Neumeister P, 2003, Mol Biol Cell, 14, 05
- Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J., 1995, Oncogene, 11, 1005
- Lu F, 2003, Cancer Res, 63, 7056
- Zhu J, 2009, Int J Oncol, 36, 39
Cited by
Montalto, F. I., & De Amicis, F. (2020) · Cells · doi:10.3390/cells9122648 · Cited by 496
“Thus, Cyclin D1 is regarded as an oncogenic driver in different types of cancers including breast cancer, lung cancer, and melanoma [9].”
BackgroundA Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076834 · Cited by 382
“Indeed, overexpression of cyclin D1, present in 50% of breast cancers, leads to CDK4/6 and ERα activations and cell cycle progression [140].”
BackgroundTGF-β signaling: critical nexus of fibrogenesis and cancer
Giarratana, A. O., Prendergast, C. M., Salvatore, M. M., & Capaccione, K. M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05411-4 · Cited by 198
“At the same time, TGF-β signaling can downregulate positive cell cycle regulators, such as cyclin D1 [15].”
BackgroundLi, X., Han, M., Zhang, H., Liu, F., Pan, Y., Zhu, J., Liao, Z., Chen, X., & Zhang, B. (2022) · Biomarker Research · doi:10.1186/s40364-021-00345-1 · Cited by 172
“In addition, Cyclin D1 could form a complex with CDK4 or CDK6, whose activity was required for cell cycle progression [116].”
BackgroundReview: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
Gareb, B., Otten, A. T., Frijlink, H. W., Dijkstra, G. D. H., & Kosterink, J. G. W. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060539 · Cited by 122
“CyD1 is a protein involved in cell proliferation [161] and is overexpressed in IBD [162,163].”
Background
Metadata
- Authors
- Tchakarska, G., & Sola, B.
- Affiliations
- McGill University Health Centre (CA)
- Inserm (FR)
- Corresponding author
- Sola, Brigitte
- ORCID
- Sola, Brigitte
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2019-12-29
- Volume
- 19
- Issue
- 2
- Pages
- 163-178
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- PMC
- PMC6961668
- OpenAlex
- W2998185943
- Cited by
- 278
- References
- 123
- Citations by year
- 2026: 24 · 2025: 53 · 2024: 62 · 2023: 55 · 2022: 47 · 2021: 28 · 2020: 9
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell Cycle (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- arXiv (Cornell University) (submittedVersion)
- HAL (submittedVersion, other-oa)
- arXiv (Cornell University)
- Funders
- Ligue contre le Cancer (CD76)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin D1, cyclin-dependent kinases, CDK4/6, non-canonical functions, tumor suppressor, DNA damage response, DNA double-strand breaks, non-homologous end joining, homologous recombination, DNA repair, cell cycle regulation, targeted therapy, cyclin D1 overexpression
- MeSH terms
- Animals, Cell Nucleus, DNA Damage, Humans, Neoplasm Invasiveness, Neoplasms, Cyclin D1, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The double dealing of cyclin D1. https://app.cochat.ai/papers/10.1080/15384101.2019.1706903
- The paper
- Tchakarska, G., & Sola, B. (2020). The double dealing of cyclin D1. Cell Cycle. https://doi.org/10.1080/15384101.2019.1706903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.